Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

Eli Lilly has announced a definitive agreement to acquire Verve Therapeutics, a gene editing company focused on single-dose treatments for cardiovascular disease, for a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve's common stock. Verve's lead program, VERVE-102, targets PCSK9, a gene linked to cholesterol levels, and is currently in Phase 1b clinical trials; Lilly aims to leverage its cardiometabolic and genetic medicine capabilities to advance Verve's pipeline and shift cardiovascular disease treatment towards one-time therapies, though the deal's impact on Lilly's 2025 financial guidance remains uncertain.

Analysis

Eli Lilly's definitive agreement to acquire Verve Therapeutics for a substantial premium, approximately 113% above Verve's 30-day volume-weighted average trading price, underscores a significant strategic investment to enhance its capabilities in genetic medicines, specifically targeting cardiovascular disease. This acquisition aligns with Lilly's existing strengths in cardiometabolic disease and genetic medicine, aiming to integrate Verve's innovative gene editing pipeline. Verve's lead program, VERVE-102, currently in Phase 1b clinical trials and granted Fast Track designation, is a potential first-in-class in vivo gene editing medicine targeting PCSK9. It holds promise for a single-dose, lifelong treatment for individuals with heterozygous familial hypercholesterolemia (HeFH), a condition affecting 1 in 250 people, and certain patients with premature coronary artery disease, potentially shifting the treatment paradigm from chronic care. The transaction has garnered strongly positive sentiment (overall score 0.8; LLY 0.7, VERV 0.9), reflecting market optimism about the synergistic potential. However, Lilly will determine the GAAP accounting treatment upon closing, and the transaction's full impact on its financial results and guidance, including its 2025 outlook, remains to be detailed.

Key Decisions for Investors

• Investors in Eli Lilly should view this acquisition as a long-term strategic commitment to pioneering gene-editing technology in the high-potential cardiovascular space, while being mindful of the significant premium paid and the inherent risks associated with early-stage drug development and integration.
• Shareholders of Verve Therapeutics are presented with a compelling tender offer reflecting a substantial premium, suggesting a favorable opportunity for value realization.
• Monitor the clinical trial progress of Verve's lead candidate, VERVE-102, as its developmental success and subsequent regulatory approvals will be critical determinants of the acquisition's long-term value and Lilly's future positioning in genetic cardiovascular therapies.
• Anticipate updates to Eli Lilly's financial guidance post-acquisition to assess the near-term impact on R&D expenditures and overall profitability projections.